Drug intelligence / Profile preview

Pneumococcal vaccine (SPB NIIVS)

Development stage: Preclinical
Lead developer: Saint Petersburg Scientific Research Institute of Vaccines and Serums
Modality: Vaccines & Immunotherapeutics

Overview

The SPB NIIVS pneumococcal vaccine is a prophylactic candidate currently in preclinical development by the St. Petersburg Institute of Vaccines and Sera (SPB NIIVS). It is designed to prevent infections caused by *Streptococcus pneumoniae*, including pneumonia and other forms of pneumococcal disease. As a vaccine, it aims to stimulate the immune system to recognize and neutralize the bacteria, thereby providing protection against subsequent exposure.

Other names: SPB NIIVS pneumococcal vaccine

Beyond the preview

Go deeper on Pneumococcal vaccine (SPB NIIVS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pneumococcal vaccine (SPB NIIVS).

Explore the full profile